HopeStage
Back to all studies
CompletedNCT07253324

ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)

This study evaluated the safety of ENX-104 for people with depression.

Medication studyAges 18–65United Kingdom
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety of ENX-104 for people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Blackpool and 3 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: February 17, 2025
Recruitment status
Completed
Enrollment listed in the registry
48
Sponsor
Engrail Therapeutics INC
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT07253324
Official title
Show the full official title

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ENX-104 in Participants With Major Depressive Disorder With Anhedonia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Blackpool · Prescot · Cannock

1 more locations
  • Manchester

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety of ENX-104 for people with depression.

Who is behind this study?

The study sponsor is Engrail Therapeutics INC.

Did this study involve medication?

Yes. The study involved medication, including ENX-104 and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies